$NHI
NATIONAL HEALTH INVESTORS INC Stock $nhi

$nhi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000087786023000066 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$77.88M	$82.39M	$70.67M
YoY Change	30.01%	15.51%	1.44%
Cost Of Revenue	$12.89M	$12.42M	$12.08M
YoY Change	14.41%	308.76%	193.18%
Gross Profit	$64.98M	$69.97M	$58.59M
YoY Change	33.63%	2.46%	-10.61%
Gross Profit Margin	83.44%	84.93%	82.91%
Selling, General & Admin	$4.738M	$5.958M	$5.326M
YoY Change	-15.59%	-41.43%	33.75%
% of Gross Profit	7.29%	8.52%	9.09%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$17.73M	$17.62M	$17.30M
YoY Change	-0.24%	-3.58%	-10.34%
% of Gross Profit	27.28%	25.18%	29.53%
Operating Expenses	$49.74M	$49.60M	$22.63M
YoY Change	0.26%	-25.08%	-2.8%
Operating Profit	$15.24M	$20.37M	$35.97M
YoY Change	-1651.93%	878.76%	-14.91%
Interest Expense	$14.19M	$14.03M	-$12.45M
YoY Change	30.68%	37.55%	7.72%
% of Operating Profit	93.14%	68.87%	-34.6%
Other Income/Expense, Net
YoY Change
Pretax Income	$39.45M	$34.18M	$1.560M
YoY Change	83.77%	314.54%	-76.02%
Income Tax
% Of Pretax Income
Net Earnings	$39.78M	$34.48M	$1.863M
YoY Change	83.54%	310.57%	-71.24%
Net Earnings / Revenue	51.08%	41.86%	2.64%
Basic Earnings Per Share	$0.92	$0.79
Diluted Earnings Per Share	$0.92	$0.79	$0.04
COMMON SHARES
Basic Shares Outstanding	43.39M shares	43.39M shares	43.39M shares
Diluted Shares Outstanding	43.39M shares	43.39M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.41M	$13.88M	$19.29M
YoY Change	-59.91%	-61.59%	-48.44%
Cash & Equivalents	$17.41M	$13.88M	$19.29M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$4.637M	$6.805M	$3.621M
Other Receivables	$82.30M	$79.10M
Total Short-Term Assets	$104.3M	$99.78M	$96.19M
YoY Change	-15.26%	-23.75%	-28.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.135B	$2.165B	$2.118B
YoY Change	-2.38%	-1.65%	-8.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$5.000M
YoY Change			0.0%
Other Assets	$15.03M	$28.32M	$45.53M
YoY Change	-74.65%	-79.14%	-33.51%
Total Long-Term Assets	$2.394B	$2.433B	$2.411B
YoY Change	-2.84%	-8.92%	-10.87%
TOTAL ASSETS
Total Short-Term Assets	$104.3M	$99.78M	$96.19M
Total Long-Term Assets	$2.394B	$2.433B	$2.411B
Total Assets	$2.498B	$2.533B	$2.507B
YoY Change	-3.43%	-9.61%	-11.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$28.95M	$24.63M	$25.91M
YoY Change	14.27%	28.85%	11.75%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$68.02M	$63.68M	$64.96M
YoY Change	3.81%	5.46%	-11.37%
LONG-TERM LIABILITIES
Long-Term Debt	$1.135B	$1.176B	$1.148B
YoY Change	2.75%	-5.85%	-7.67%
Other Long-Term Liabilities	$5.284M	$4.944M	$5.052M
YoY Change	23.4%	15.38%	-11.76%
Total Long-Term Liabilities	$1.140B	$1.181B	$1.153B
YoY Change	2.82%	-5.77%	-7.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$68.02M	$63.68M	$64.96M
Total Long-Term Liabilities	$1.140B	$1.181B	$1.153B
Total Liabilities	$1.208B	$1.245B	$1.218B
YoY Change	2.88%	-5.26%	-7.9%
SHAREHOLDERS EQUITY
Retained Earnings	$2.405B	$2.366B	$2.331B
YoY Change
Common Stock	$1.602B	$1.602B	$1.600B
YoY Change	0.27%	0.31%	0.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.269B	$1.267B	$1.270B
YoY Change
Total Liabilities & Shareholders Equity	$2.498B	$2.533B	$2.507B
YoY Change	-3.43%	-9.61%	-11.68%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	$39.78M	$34.48M	$1.863M
YoY Change	83.54%	310.57%	-71.24%
Depreciation, Depletion And Amortization	$17.73M	$17.62M	$17.30M
YoY Change	-0.24%	-3.58%	-10.34%
Cash From Operating Activities	$50.50M	$31.05M	$46.36M
YoY Change	-11.05%	-19.73%	-13.12%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$38.08M	$1.488M
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$33.50M	$10.56M	-$47.71M
YoY Change	-83.18%	-612.62%	-317.67%
Cash From Investing Activities	$33.50M	-$27.52M	-$49.20M
YoY Change	-82.76%	1235.97%	-324.45%
FINANCING ACTIVITIES
Cash Dividend Paid		$39.05M
YoY Change		-5.37%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$145.1M
YoY Change		93.22%
Cash From Financing Activities	-80.25M	-$9.516M	-7.357M
YoY Change	-67.23%	-73.7%	-91.44%
NET CHANGE
Cash From Operating Activities	50.50M	$31.05M	46.36M
Cash From Investing Activities	33.50M	-$27.52M	-49.20M
Cash From Financing Activities	-80.25M	-$9.516M	-7.357M
Net Change In Cash	3.747M	-$5.989M	-10.20M
YoY Change	-38.89%	-1451.92%	-4.78%
FREE CASH FLOW
Cash From Operating Activities	$50.50M	$31.05M	$46.36M
Capital Expenditures	$0.00	$38.08M	$1.488M
Free Cash Flow	$50.50M	-$7.033M	$44.87M
YoY Change	-18.08%	-118.18%	-15.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000877860
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-10822
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	National Health Investors Inc
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MD
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	62-1470956
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	222 Robert Rose Drive
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Murfreesboro
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37129
CY2023Q1	dei	City Area Code CityAreaCode	(615)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	890-9100
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	NHI
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43388742	shares
CY2023Q1	us-gaap	Land Land	181949000	usd
CY2022Q4	us-gaap	Land Land	177527000	usd
CY2023Q1	us-gaap	Investment Building And Building Improvements InvestmentBuildingAndBuildingImprovements	2604742000	usd
CY2022Q4	us-gaap	Investment Building And Building Improvements InvestmentBuildingAndBuildingImprovements	2549019000	usd
CY2023Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	3924000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	3352000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2790615000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2729898000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	625743000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	611688000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2164872000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2118210000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	14964000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	15338000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss	219942000	usd
CY2022Q4	us-gaap	Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss	233141000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13875000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19291000	usd
CY2023Q1	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	79103000	usd
CY2022Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	76895000	usd
CY2023Q1	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	26670000	usd
CY2022Q4	us-gaap	Real Estate Heldforsale RealEstateHeldforsale	43302000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	28768000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	16585000	usd
CY2023Q1	us-gaap	Assets Assets	2533230000	usd
CY2022Q4	us-gaap	Assets Assets	2507424000	usd
CY2023Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1176014000	usd
CY2022Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1147511000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	24626000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	25905000	usd
CY2023Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	39050000	usd
CY2022Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	39050000	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	4944000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	5052000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1244634000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1217518000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	9520000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	9825000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43388742	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43388742	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43388742	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43388742	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	434000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	434000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1601257000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1599427000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2365674000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2331190000	usd
CY2023Q1	us-gaap	Cumulative Dividends CumulativeDividends	2699876000	usd
CY2022Q4	us-gaap	Cumulative Dividends CumulativeDividends	2660826000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1267489000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1270225000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	11587000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2022Q4	us-gaap	Minority Interest MinorityInterest	9856000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1279076000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1280081000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2533230000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2507424000	usd
CY2023Q1	us-gaap	Lease Income LeaseIncome	65299000	usd
CY2022Q1	us-gaap	Lease Income LeaseIncome	64559000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11700000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	5389000	usd
CY2022Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	6768000	usd
CY2023Q1	us-gaap	Revenues Revenues	82388000	usd
CY2022Q1	us-gaap	Revenues Revenues	71327000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	17617000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	18272000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	14027000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	10198000	usd
CY2023Q1	nhi	Senior Housing Operating Expenses SeniorHousingOperatingExpenses	9799000	usd
CY2022Q1	nhi	Senior Housing Operating Expenses SeniorHousingOperatingExpenses	0	usd
CY2023Q1	nhi	Litigation Settlement Expense Benefit LitigationSettlementExpenseBenefit	122000	usd
CY2022Q1	nhi	Litigation Settlement Expense Benefit LitigationSettlementExpenseBenefit	1827000	usd
CY2023Q1	nhi	Franchise Excise And Other Taxes FranchiseExciseAndOtherTaxes	183000	usd
CY2022Q1	nhi	Franchise Excise And Other Taxes FranchiseExciseAndOtherTaxes	244000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5653000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8101000	usd
CY2023Q1	us-gaap	Real Estate Taxes And Insurance RealEstateTaxesAndInsurance	2619000	usd
CY2022Q1	us-gaap	Real Estate Taxes And Insurance RealEstateTaxesAndInsurance	3038000	usd
CY2023Q1	nhi	Loanand Lease Lossesand Recoveries Net LoanandLeaseLossesandRecoveriesNet	-418000	usd
CY2022Q1	nhi	Loanand Lease Lossesand Recoveries Net LoanandLeaseLossesandRecoveriesNet	24528000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	49602000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	66208000	usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	1397000	usd
CY2022Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	2981000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-151000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	297000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	34183000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	8246000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-301000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-153000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	34484000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	8399000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43388742	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45850686	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43391429	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45851061	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2023Q1	us-gaap	Profit Loss ProfitLoss	34183000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	8246000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	17617000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	18272000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1048000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1087000	usd
CY2023Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	148000	usd
CY2022Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	120000	usd
CY2023Q1	nhi	Amortization Of Lease Inducements AmortizationOfLeaseInducements	299000	usd
CY2022Q1	nhi	Amortization Of Lease Inducements AmortizationOfLeaseInducements	252000	usd
CY2023Q1	us-gaap	Straight Line Rent StraightLineRent	2097000	usd
CY2022Q1	us-gaap	Straight Line Rent StraightLineRent	1079000	usd
CY2023Q1	nhi	Noncash Rental Income NoncashRentalIncome	2500000	usd
CY2022Q1	nhi	Noncash Rental Income NoncashRentalIncome	0	usd
CY2023Q1	us-gaap	Other Noncash Income OtherNoncashIncome	376000	usd
CY2022Q1	us-gaap	Other Noncash Income OtherNoncashIncome	880000	usd
CY2023Q1	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	0	usd
CY2022Q1	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-8838000	usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	1397000	usd
CY2022Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	2981000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	297000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-151000	usd
CY2023Q1	nhi	Loanand Lease Lossesand Recoveries Net LoanandLeaseLossesandRecoveriesNet	-418000	usd
CY2022Q1	nhi	Loanand Lease Lossesand Recoveries Net LoanandLeaseLossesandRecoveriesNet	24528000	usd
CY2023Q1	nhi	Payment Of Tenant Lease Incentives PaymentOfTenantLeaseIncentives	10000000	usd
CY2022Q1	nhi	Payment Of Tenant Lease Incentives PaymentOfTenantLeaseIncentives	0	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2105000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5083000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3772000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	107000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3277000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4252000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-219000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-385000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31048000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	38680000	usd
CY2023Q1	us-gaap	Payments To Acquire Mortgage Notes Receivable PaymentsToAcquireMortgageNotesReceivable	7219000	usd
CY2022Q1	us-gaap	Payments To Acquire Mortgage Notes Receivable PaymentsToAcquireMortgageNotesReceivable	16350000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Collection Of Mortgage Notes Receivable ProceedsFromSaleAndCollectionOfMortgageNotesReceivable	7211000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Collection Of Mortgage Notes Receivable ProceedsFromSaleAndCollectionOfMortgageNotesReceivable	988000	usd
CY2023Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	38081000	usd
CY2022Q1	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Wholly Owned Real Estate And Real Estate Acquired In Settlement Of Loans ProceedsFromSaleOfWhollyOwnedRealEstateAndRealEstateAcquiredInSettlementOfLoans	10201000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Wholly Owned Real Estate And Real Estate Acquired In Settlement Of Loans ProceedsFromSaleOfWhollyOwnedRealEstateAndRealEstateAcquiredInSettlementOfLoans	13170000	usd
CY2023Q1	nhi	Payments To Renovate Real Estate PaymentsToRenovateRealEstate	2133000	usd
CY2022Q1	nhi	Payments To Renovate Real Estate PaymentsToRenovateRealEstate	165000	usd
CY2023Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	2500000	usd
CY2022Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	297000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27521000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2060000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	192000000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	85000000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	19000000	usd
CY2022Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	145103000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	75098000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4535000	usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	363000	usd
CY2022Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	271000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	39050000	usd
CY2022Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	41266000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7000	usd
CY2023Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2000000	usd
CY2022Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9516000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-36177000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5989000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	443000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21516000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39485000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15527000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39928000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	15878000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	12920000	usd
CY2023Q1	nhi	Noncash Or Part Noncash Acquisition Real Estate Acquired In Exchange Of Mortgage Receivable NoncashOrPartNoncashAcquisitionRealEstateAcquiredInExchangeOfMortgageReceivable	14200000	usd
CY2022Q1	nhi	Noncash Or Part Noncash Acquisition Real Estate Acquired In Exchange Of Mortgage Receivable NoncashOrPartNoncashAcquisitionRealEstateAcquiredInExchangeOfMortgageReceivable	0	usd
CY2023Q1	nhi	Noncash Or Part Noncash Acquisition Change In Other Assets Related To Real Estate Sales NoncashOrPartNoncashAcquisitionChangeInOtherAssetsRelatedToRealEstateSales	0	usd
CY2022Q1	nhi	Noncash Or Part Noncash Acquisition Change In Other Assets Related To Real Estate Sales NoncashOrPartNoncashAcquisitionChangeInOtherAssetsRelatedToRealEstateSales	-33000	usd
CY2023Q1	nhi	Changein Accounts Payable Investmentsin Real Estate Construction ChangeinAccountsPayableInvestmentsinRealEstateConstruction	20000	usd
CY2022Q1	nhi	Changein Accounts Payable Investmentsin Real Estate Construction ChangeinAccountsPayableInvestmentsinRealEstateConstruction	0	usd
CY2023Q1	nhi	Change In Accounts Payable Renovations Of Existing Real Estate ChangeInAccountsPayableRenovationsOfExistingRealEstate	0	usd
CY2022Q1	nhi	Change In Accounts Payable Renovations Of Existing Real Estate ChangeInAccountsPayableRenovationsOfExistingRealEstate	-219000	usd
CY2023Q1	nhi	Change In Accounts Payable Related To Distributions To Noncontrolling Interests ChangeInAccountsPayableRelatedToDistributionsToNoncontrollingInterests	90000	usd
CY2022Q1	nhi	Change In Accounts Payable Related To Distributions To Noncontrolling Interests ChangeInAccountsPayableRelatedToDistributionsToNoncontrollingInterests	-28000	usd
CY2023Q1	nhi	Reclassification Of Prepaid Equity Issuance Costs To Capital In Excess Of Par Value ReclassificationOfPrepaidEquityIssuanceCostsToCapitalInExcessOfParValue	275000	usd
CY2022Q1	nhi	Reclassification Of Prepaid Equity Issuance Costs To Capital In Excess Of Par Value ReclassificationOfPrepaidEquityIssuanceCostsToCapitalInExcessOfParValue	0	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1280081000	usd
CY2023Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	2000000	usd
CY2023Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	273000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-305000	usd
CY2023Q1	nhi	Comprehensive Income Loss Net Of Tax Excluding Loss Attributable To Noncontrolling Interest ComprehensiveIncomeLossNetOfTaxExcludingLossAttributableToNoncontrollingInterest	34488000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-275000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2105000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.90
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	39050000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1279076000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1516983000	usd
CY2022Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	243000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	8246000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5083000	usd
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.90
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	41265000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1488797000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	nhi	Number Of Real Estate Properties Classified As Held For Sale NumberOfRealEstatePropertiesClassifiedAsHeldForSale	10	property
CY2023Q1	nhi	Number Of Health Care Properties Related To Mortgage Notes Receivables NumberOfHealthCarePropertiesRelatedToMortgageNotesReceivables	14	mortgage
CY2023Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	234900000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	15000000	usd
CY2023Q1	nhi	Number Of Joint Ventures NumberOfJointVentures	2	jointventure
CY2023Q1	nhi	Number Of Real Estate Partnerships NumberOfRealEstatePartnerships	2	realestatepartnership
CY2023Q1	nhi	Variable Interest Entity Number Of Entities Not Primary Beneficiary VariableInterestEntityNumberOfEntitiesNotPrimaryBeneficiary	9	entity
CY2022Q4	nhi	Number Of Real Estate Partnerships NumberOfRealEstatePartnerships	2	property
CY2022Q4	us-gaap	Cash Cash	19291000	usd
CY2021Q4	us-gaap	Cash Cash	37412000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2225000	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In prior years, the Company presented "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumulative dividends in excess of net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" as a single line item on the Consolidated Balance Sheets and Consolidated Statements of Equity. Beginning January 1, 2023, the Company separated this line item into two components, "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumulative dividends,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" and reclassified prior year information to conform to the current period presentation.</span></div>
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	2073000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21516000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39485000	usd
CY2023Q1	us-gaap	Cash Cash	13875000	usd
CY2022Q1	us-gaap	Cash Cash	36121000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1652000	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	3807000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15527000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39928000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our credit risks primarily relate to cash and cash equivalents and investments in mortgage and other notes receivable. Cash and cash equivalents are primarily held in bank accounts and overnight investments. We maintain our bank deposit accounts with large financial institutions in amounts that may exceed federally insured limits. We have not experienced any losses in such accounts. Our mortgages and other notes receivable consist primarily of secured loans on facilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments, principally our investments in notes receivable, are subject to the possibility of loss of the carrying values as a result of the failure of other parties to perform according to their contractual obligations which may make the instruments less valuable. We obtain collateral in the form of mortgage liens and other protective rights for notes receivable and continually monitor these rights in order to reduce such possibilities of loss. We evaluate the need to provide for reserves for potential losses on our financial instruments based on management’s periodic review of our portfolio on an instrument-by-instrument basis.</span></div>
CY2023Q1	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	300000	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	24600000	usd
CY2023Q1	us-gaap	Revenue Recognition Leases RevenueRecognitionLeases	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rental Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our leases generally provide for rent escalators throughout the term of the lease. Base rental income is recognized using the straight-line method over the term of the lease to the extent that lease payments are considered collectible and the lease provides for specific contractual escalators. Under certain leases, we receive additional contingent rent, which is calculated on the increase in revenues of the tenant over a base year or base quarter. We recognize contingent rent annually or quarterly based on the actual revenues of the tenant once the target threshold has been achieved. Lease payments that depend on a factor directly related to future use of the property, such as an increase in annual revenues over a base year, are considered to be contingent rentals and are excluded from the schedule of minimum lease payments.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company reviews its operating lease receivables for collectability on a regular basis, taking into consideration changes in factors such as the tenant’s payment history, the financial condition of the tenant, business conditions in which the tenant operates and economic conditions in the area where the property is located. In the event that collectability with respect to any tenant is not probable, a direct write-off of the receivable is made as an adjustment to rental income and any future rental revenue is recognized only when the tenant makes a rental payment.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we had three tenants, including Bickford Senior Living (“Bickford”) on the cash basis of revenue recognition for their lease arrangements. Reference Note 3 for further discussion.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resident Fees and Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Resident fee revenue associated with our SHOP activities is recognized as the related performance obligations are satisfied and includes resident room charges, community fees and other resident charges. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Residency agreements are generally short term (30 days to one year), and entitle the resident to certain room and care services for a monthly fee billed in advance. Revenue for certain related services is billed monthly in arrears. The Company has elected the lessor practical expedient within Accounting Standards Codification (“ASC”) 842, Leases, not to separate the lease and nonlease components within our resident agreements as the timing and pattern of transfer to the resident are the same. The Company has determined that the nonlease component is the predominant component within the contract and will recognize revenue under ASC 606, Revenue Recognition from Contracts with Customers.</span></div>
CY2023Q1	nhi	Number Of Tenants Cash Basis Revenue Recognition NumberOfTenantsCashBasisRevenueRecognition	3	tenant
CY2023Q1	us-gaap	Revenue Recognition Interest RevenueRecognitionInterest	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">from Mortgage and Other Notes Receivable </span>Interest income is recognized based on the interest rates and principal amounts outstanding on the notes receivable. We identify a mortgage loan as non-performing if a required payment is not received within 30 days of the date it is due and a borrower’s current financial condition indicates a probability it cannot pay its current contractual amounts. A non-performing loan is returned to accrual status at such time as the loan becomes contractually current and management believes all future principal and interest will be received according to the contractual loan terms.
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	202028000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	14200000	usd
CY2023Q1	nhi	Number Of Real Estate Properties Classified As Held For Sale NumberOfRealEstatePropertiesClassifiedAsHeldForSale	10	property
CY2022Q4	nhi	Number Of Real Estate Properties Classified As Held For Sale NumberOfRealEstatePropertiesClassifiedAsHeldForSale	13	property
CY2023Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	26670000	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	43302000	usd
CY2023Q1	nhi	Nonportfolio Assets Original Cost NonportfolioAssetsOriginalCost	2600000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	15000000	usd
CY2023Q1	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	2448934000	usd
CY2023Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	234906000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11700000	usd
CY2023Q1	nhi	Percentage Of Continuing Revenue PercentageOfContinuingRevenue	0.14
CY2022Q1	nhi	Percentage Of Continuing Revenue PercentageOfContinuingRevenue	0
CY2023Q1	us-gaap	Revenues Revenues	82388000	usd
CY2022Q1	us-gaap	Revenues Revenues	71327000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	171434000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	239886000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	243414000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	250071000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	208445000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received Thereafter LessorOperatingLeasePaymentsToBeReceivedThereafter	663295000	usd
CY2023Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1978573000	usd
CY2023Q1	us-gaap	Lease Income LeaseIncome	65299000	usd
CY2022Q1	us-gaap	Lease Income LeaseIncome	64559000	usd
CY2023Q1	nhi	Number Of Health Care Properties Related To Mortgage Notes Receivables NumberOfHealthCarePropertiesRelatedToMortgageNotesReceivables	14	property
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	15000000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	14964000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss	219942000	usd
CY2023Q1	nhi	Probability Of Default Increase Current Conditions Adjustment ProbabilityOfDefaultIncreaseCurrentConditionsAdjustment	0.20
CY2023Q1	nhi	Probability Of Default Increase Current Conditions Adjustment ProbabilityOfDefaultIncreaseCurrentConditionsAdjustment	0.20
CY2023Q1	nhi	Estimated Credit Losses Current Conditions Adjustment Combined EstimatedCreditLossesCurrentConditionsAdjustmentCombined	0.44
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	15338000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Credit Loss Expense Reversal FinancingReceivableExcludingAccruedInterestCreditLossExpenseReversal	-374000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	14964000	usd
CY2023Q1	nhi	Annual Fixed Preferred Return AnnualFixedPreferredReturn	10200000	usd
CY2022Q4	us-gaap	Equity Method Investment Difference Between Carrying Amount And Underlying Equity EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity	-5000000	usd
CY2023Q1	us-gaap	Equity Method Investment Difference Between Carrying Amount And Underlying Equity EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity	-5000000	usd
CY2023Q1	nhi	Equity Method Investment Unrealized Gain Loss On Disposal EquityMethodInvestmentUnrealizedGainLossOnDisposal	-600000	usd
CY2022Q1	nhi	Equity Method Investment Unrealized Gain Loss On Disposal EquityMethodInvestmentUnrealizedGainLossOnDisposal	-600000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2023Q1	nhi	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	extensionoption
CY2023Q1	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	13200000	usd
CY2023Q1	us-gaap	Incentive To Lessee IncentiveToLessee	12891000	usd
CY2022Q4	us-gaap	Incentive To Lessee IncentiveToLessee	3190000	usd
CY2023Q1	us-gaap	Escrow Deposit EscrowDeposit	6208000	usd
CY2022Q4	us-gaap	Escrow Deposit EscrowDeposit	6208000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1652000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	2225000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	28768000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	16585000	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	215000000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	42000000	usd
CY2023Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	8013000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	8538000	usd
CY2023Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1176014000	usd
CY2022Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1147511000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	270305000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths	75425000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo	125816000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree	215000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour	100000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Rolling After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive	400000000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1186546000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2519000	usd
CY2023Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	8013000	usd
CY2023Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1176014000	usd
CY2023Q1	nhi	Debt Leverage Limit Coupon Change Trigger DebtLeverageLimitCouponChangeTrigger	0.50
CY2023Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	13440000	usd
CY2022Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9558000	usd
CY2023Q1	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	19000	usd
CY2022Q1	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	2000	usd
CY2023Q1	nhi	Amortization Of Financing Costs Exclusive Of Amounts Written Off AmortizationOfFinancingCostsExclusiveOfAmountsWrittenOff	606000	usd
CY2022Q1	nhi	Amortization Of Financing Costs Exclusive Of Amounts Written Off AmortizationOfFinancingCostsExclusiveOfAmountsWrittenOff	642000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	14027000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	10198000	usd
CY2023Q1	us-gaap	Loans And Leases Receivable Commitments Fixed Rates LoansAndLeasesReceivableCommitmentsFixedRates	145400000	usd
CY2023Q1	nhi	Maximum Commitment For All Active Development Projects MaximumCommitmentForAllActiveDevelopmentProjects	23200000	usd
CY2023Q1	us-gaap	Development In Process DevelopmentInProcess	17100000	usd
CY2023Q1	nhi	Cash Consideration Of An Ongoing Property Tax Appeal CashConsiderationOfAnOngoingPropertyTaxAppeal	800000	usd
CY2023Q1	nhi	Contingent Funding Commitment Amount Funded ContingentFundingCommitmentAmountFunded	1000000	usd
CY2023Q1	nhi	Contingent Funding Commitment ContingentFundingCommitment	15900000	usd
CY2023Q1	us-gaap	Off Balance Sheet Credit Loss Liability Credit Loss Expense Reversal OffBalanceSheetCreditLossLiabilityCreditLossExpenseReversal	-382000	usd
CY2023Q1	us-gaap	Off Balance Sheet Credit Loss Liability OffBalanceSheetCreditLossLiability	301000	usd
CY2022Q2	nhi	Number Of Real Estate Properties Disposal Transactions NumberOfRealEstatePropertiesDisposalTransactions	3	property
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	9825000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-305000	usd
CY2023Q1	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	9520000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	160000000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P1Y
CY2023Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2468354	shares
CY2023Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	151600000
CY2023Q1	nhi	Common Stock Value Maximum Issuance CommonStockValueMaximumIssuance	500000000	usd
CY2022Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.90
CY2023Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.90
CY2021Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.90
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.90
CY2023Q1	nhi	Share Based Payment Arrangement Number Of Incentive Plans ShareBasedPaymentArrangementNumberOfIncentivePlans	2	plan
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2105000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5083000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.56
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.81
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	693000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.070
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.071
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.397
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.492
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y10M24D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y10M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0465
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0172
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1652505	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	78.10
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	53.41
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7500	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	53.41
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	23000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	62.33
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2240507	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	70.71
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1719487	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	74.34
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2216175	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	70.97
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	74.67
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	60002	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	64.33
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2516673	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	68.61
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y11M19D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2132828	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	71.21
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y8M12D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q1	nhi	Aggregate Intrinsic Value Per Share Options Exercised AggregateIntrinsicValuePerShareOptionsExercised	4.94
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3500000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	34484000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	8399000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43388742	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45850686	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	43388742	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	45850686	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2687	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	375	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43391429	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45851061	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.18
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	728524	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	481068	shares
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.90
CY2022Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.90
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	operatingsegment
CY2023Q1	us-gaap	Lease Income LeaseIncome	65299000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11700000	usd
CY2023Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	5389000	usd
CY2023Q1	us-gaap	Revenues Revenues	82388000	usd
CY2023Q1	nhi	Senior Housing Operating Expenses SeniorHousingOperatingExpenses	9799000	usd
CY2023Q1	us-gaap	Real Estate Taxes And Insurance RealEstateTaxesAndInsurance	2619000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	69970000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	17617000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	14027000	usd
CY2023Q1	nhi	Litigation Settlement Expense Benefit LitigationSettlementExpenseBenefit	122000	usd
CY2023Q1	nhi	Franchise Excise And Other Taxes FranchiseExciseAndOtherTaxes	183000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5653000	usd
CY2023Q1	nhi	Loanand Lease Lossesand Recoveries Net LoanandLeaseLossesandRecoveriesNet	-418000	usd
CY2023Q1	us-gaap	Gains Losses On Sales Of Investment Real Estate GainsLossesOnSalesOfInvestmentRealEstate	1397000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	34183000	usd
CY2023Q1	us-gaap	Assets Assets	2533230000	usd

Files In Submission

Name	View Source	Status
nhi-20230331_cal.xml	Edgar Link	unprocessable
nhi-20230331_def.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
0000877860-23-000066-index-headers.html	Edgar Link	pending
0000877860-23-000066-index.html	Edgar Link	pending
0000877860-23-000066.txt	Edgar Link	pending
0000877860-23-000066-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nhi-20230331.htm	Edgar Link	pending
nhi-20230331.xsd	Edgar Link	pending
nhi-3312023x10qex311.htm	Edgar Link	pending
nhi-3312023x10qex312.htm	Edgar Link	pending
nhi-3312023x10qex32.htm	Edgar Link	pending
nhiamendedandrestatedbylaws.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
nhi-20230331_lab.xml	Edgar Link	unprocessable
nhi-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
nhi-20230331_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NHI
NATIONAL HEALTH INVESTORS INC Stock $nhi

2023 Q2 Form 10-Q Financial Statement

#000087786023000066 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NHI NATIONAL HEALTH INVESTORS INC Stock $nhi

2023 Q2 Form 10-Q Financial Statement

#000087786023000066 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NHI
NATIONAL HEALTH INVESTORS INC Stock $nhi